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Numerous compositional models of the tear film have 
been proposed. The first description by Wolff [1] in 1946 
presented a three-layered tear film, consisting of an anterior 
lipid layer, a middle aqueous layer, and an inner mucin layer. 
As additional information became available, this model 
evolved to accommodate the possibility of soluble mucins 
in the aqueous layer, decreasing in concentration toward the 
lipid layer [2]. The present concept is that the tear film is a 
bilayered structure, consisting of an aqueous/mucinous phase 
and an outermost multilayered lipid phase [3].
Of the various components of the tear film, mucins are 
thought to play a key role in the retention of water and other 
tear fluid components on the ocular surface, facilitating a 
healthy, wet ocular surface. To date, at least 20 different 
mucin subtypes have been characterized [4-13], and of these, 
the secreted (mucin 2, cell surface associated [MUC2], 
MUC5AC, MUC5B, MUC7) and membrane-bound (MUC1, 
MUC4, MUC16) forms are expressed by ocular surface 
epithelia [14,15]. Of the mucins identified on the ocular 
surface, goblet cell–derived MUC5AC and three membrane-
bound forms (MUC1, MUC4, MUC16) are the most relevant 
for maintaining a normal tear film [14]. Specifically, data 
support a role for mucins in such critical tasks as clearing 
debris and pathogens, protecting the corneal and conjunctival 
epithelium, preventing bacterial adhesion, and promoting 
boundary lubrication [16]. More recent evidence supports the 
fact that the ectodomain of each membrane-bound species 
is constitutively released into the tear film, forming soluble 
versions of these molecules. To date, the biologic role(s) asso-
ciated with these soluble species have yet to be elucidated 
[17-21].
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Purpose: To quantify the expression of mucin 1, cell surface associated (MUC1) and mucin 16, cell surface associated 
(MUC16) proteins and messenger ribonucleic acid (mRNA) in a cohort of postmenopausal women (PMW), to explore 
the relationship between mucin expression, dry eye symptomology, and tear stability.
Methods: Thirty-nine healthy PMW (>50 years of age) were enrolled in this study. No specific inclusion criteria were 
used to define dry eye; instead, a range of subjects were recruited based on responses to the Allergan Ocular Surface 
Disease Index (OSDI) questionnaire and tear stability measurements as assessed by non-invasive tear breakup time 
(NITBUT). Tears were collected from the inferior tear meniscus using a disposable glass capillary tube, and total 
RNA and total protein were isolated from conjunctival epithelial cells collected via impression cytology. Expression of 
membrane-bound and soluble MUC1 and MUC16 were quantified with western blotting, and expression of MUC1 and 
MUC16 mRNA was assessed with real-time PCR.
Results: OSDI responses ranged from 0 to 60, and NITBUT ranged from 18.5 to 2.9 s. Only two statistically significant 
correlations were found: soluble MUC16 protein concentration and MUC16 mRNA expression with OSDI vision related 
(−0.47; p=0.01) and ocular symptom (0.39; p=0.02) subscores, respectively. Post hoc exploratory analysis on absolute 
expression values was performed on two subsets of subjects defined as asymptomatic (OSDI ≤6, n=12) and moderate 
to severe symptomatic (OSDI ≥20, n=12). The only significant difference between the two subgroups was a significant 
reduction in MUC16 mRNA expression found in the symptomatic dry eye group (1.52±1.19 versus 0.57±0.44; p=0.03).
Conclusions: A broad exploration of mucin expression compared to either a sign (NITBUT) or symptoms of dry eye 
failed to reveal compelling evidence supporting a significant relationship, other than a potential association between 
MUC16 with specific symptoms. Furthermore, comparison of mucin protein and expression levels between the asymp-
tomatic and moderate to severe symptomatic subgroups revealed only one significant difference, a reduction in MUC16 
mRNA expression in the symptomatic subgroup.
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Alteration in mucin expression or mucin glycosyl-
ation has been implicated in the pathophysiology of dry 
eye. Reduction in the concentration of goblet cell–derived 
MUC5AC [22-24], membrane-bound or soluble forms of 
MUC1 and MUC16 [20,21,25-27], and conjunctival MUC1, 
MUC2, MUC4, and MUC5AC messenger ribonucleic acid 
(mRNA) [28] have been reported. Complicating the inter-
pretation of these studies are various variables, including 
multiple study sub-populations (Sjögren’s syndrome, contact 
lens wearers, symptomatic young adults, keratoconjunctivitis 
sicca), varied dry eye inclusion criteria, multiple tear and 
conjunctival sample collection methods, and small sample 
sizes. Contradictory data also exist in the literature, where 
no change [20,21,25,29] or an increase in mucin mRNA 
or protein concentration [20,21] has been reported. Such 
apparent contradictions can seem more obvious when three 
different populations are compared simultaneously, as in the 
studies by Caffery et al. [20,21]. In these studies, patients 
with Sjögren’s syndrome routinely displayed higher amounts 
of soluble mucin and mRNA coding for MUC1 and MUC16 
compared to the other two groups whereas generally no 
difference was found between mucin amounts when the non-
Sjögren’s keratoconjunctivitis sicca (KCS) and control groups 
were compared. Last, despite the proposed importance of 
mucins in maintaining a healthy ocular surface and tear film, 
data supporting a correlation between mucin expression and 
signs or symptoms of dry eye are lacking [20,21,25,29]. Taken 
together, conclusions regarding the etiological or pathophysi-
ological relevance between aberrant mucin expression and 
dry eye have been difficult to draw. Given the potential that 
a specific mucin mRNA or protein species could serve as a 
quantitative indicator of dry eye [28] or as a target for the 
therapeutic treatment of dry eye [30,31], additional studies 
seem prudent.
The results of large epidemiological studies [32] 
conducted in the United States clearly suggest that the 
prevalence of dry eye is greater in women than in men, and 
that women frequently consult clinicians with symptoms of 
ocular dryness and discomfort [33,34]. To date, only one 
large study has focused on postmenopausal women (PMW) 
complaining of dry eye disease [25]. In this study, PMW 
with a history of dry eye displayed significantly increased 
membrane-bound MUC1 and MUC16 protein and MUC1 
mRNA levels compared to asymptomatic controls, prompting 
the hypothesis that increased mucin concentration may be a 
compensatory response to irritation.
In light of all the data presented above, the aim of this 
study was to further explore MUC1 and MUC16 protein and 
mRNA concentrations in a group of PMW. Given that signs 
and symptoms of dry eye are notoriously uncorrelated and 
little to no consistency exists in the literature regarding study 
design, we enrolled a cohort of PMW that would span a range 
of symptoms as well as one key sign of dry eye, tear stability. 
Tear stability was chosen based on the hypothesis that mucin 
significantly aids in aqueous adherence to the ocular surface, 
and thus, we rationalized that a reduction in tear film mucin 
concentration may be clinically characterized with alterations 
in the non-invasive tear break-up time (NITBUT).
METHODS
Participants: This study received approval from the Univer-
sity of Waterloo’s Office of Research Ethics before initiation, 
and informed consent was obtained from all participants 
according to the tenets of the Declaration of Helsinki. A 
case history and complete ocular surface examination were 
performed to determine participant eligibility. Participants on 
hormone replacement therapy (HRT) were excluded, as were 
contact lens wearers and participants receiving any topical 
ocular medication or systemic medication known to exacer-
bate dry eye. Participants with a prior history of blepharitis 
or active blepharitis at the time of recruitment were also 
excluded from the study. “Postmenopausal” was defined as no 
menses for at least 1 year, not associated with hysterectomy. 
Thirty-nine healthy postmenopausal women (PMW) greater 
than 50 years of age were recruited (age range= 50-70 years).
Subjective and objective clinical measurements: To assess 
symptoms, participants completed the Allergan Ocular 
Surface Disease Index (OSDI) questionnaire [35]. Tear 
stability was assessed by performing a NITBUT evaluation 
using the ALCON EyeMap (Model EH-290 Topography 
System, ALCON Inc., Fort Worth, TX). The keratoscope 
unit produces concentric rings of light, which are reflected 
off the cornea and imaged through a charge-coupled device 
(CCD) camera. NITBUT was quantified by measuring the 
time taken for distortions or discontinuities to appear in the 
reflected image of the concentric ring pattern. The time (in 
seconds) for the tear film to rupture (and thus distort the 
rings) was measured using a stopwatch, to the nearest 0.1 of 
a second. Three measurements were taken in each eye, and 
the overall average of both eyes was used for analysis.
Analytical techniques:
Reagents and materials—Agarose was from Cambrex 
Bio Science (Rockland, ME). Molecular weight standards 
(HiMark prestained protein standard) were from Invitrogen 
(Carlsbad, CA). ECL-Plus kits were from GE Healthcare 
(Baie d’Urfe, Canada). The 10X Complete protease inhibitor 
cocktail was from Roche (Mannheim, Germany). The DC 
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Protein Assay Kit was from BioRad Laboratories (Missis-
sauga, Canada). Mouse monoclonal antihuman MUC1 anti-
body (DF3) was from Signet (Dedham, MA), monoclonal 
mouse antihuman MUC16 antibody (OC125) was from 
DAKO (Glostrup, Denmark), and goat antimouse immu-
noglobulin G horseradish peroxidase was from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA). MUC16 standard 
antigen (CA125) and MUC1 standard antigen (CA15–3) were 
from Biodesign (Memphis, TN). The 0.45 μM pore Millipore 
Membrane Filters were from Millipore (Billerica, MA). The 
RNeasy Mini kit including RLT RNA Isolation buffer was 
from Qiagen Inc. (Mississauga, Canada). The SuperScript 
III First-Strand Synthesis System for real-time PCR (RT–
PCR) was from Invitrogen (Carlsbad, CA), and the TaqMan 
Universal PCR Master Mix was from Applied Biosystems 
(Foster City, CA). DC Protein Assay kit was purchased from 
Biorad, Mississauga, Canada). All other chemicals were 
purchased from Sigma-Aldrich, (Oakville, Canada).
Capillary tear collection: Using a graduated disposable 5 μl 
microcapillary tube (Wiretol-Micropipettes, Drummond 
Scientific Co., Broomall, PA), up to 5 μl of tears per eye were 
collected from the inferior temporal tear meniscus of each 
participant, without corneal anesthesia. Tears from both eyes 
were pooled and immediately placed on dry ice until transfer 
to −80 °C for storage.
Conjunctival impression cytology: Following topical anes-
thesia (Alcaine, Alcon), epithelial cells were collected via 
impression cytology of the superior and temporal conjunc-
tiva from each eye using sterile membrane filters cut to 
approximately 9 mm diameter circles. The two conjunctival 
impression cytology (CIC) samples from the right eye were 
placed in 1 ml of RLT RNA Isolation Buffer containing 
0.01% β-mercaptoethanol, whereas the two left eye samples 
were placed in an empty sterile 2 ml tube, thus facilitating 
the isolation of total RNA and total protein, respectively. All 
samples were immediately placed on dry ice and then trans-
ferred to −80 °C for storage until processing.
Protein isolation from conjunctival impression cytology 
samples: Total protein was isolated using 75 µl of extraction 
buffer (2% w/v sodium dodecyl sulfate [SDS]), 1X Complete 
protease inhibitor cocktail in 50 mM Tris-HCL buffer pH 
7.4 (Tris: 2-Amino-2-hydroxymethyl-propane-1,3-diol). 
Following vigorous mixing, the samples were heated at 95 °C 
for 10 min. Tubes were centrifuged at 12 000 × g (RCF) for 
6 min. Then the protein extract was collected, transferred to 
a fresh, capped polypropylene centrifuge tube, and frozen at 
−80 °C until analysis.
Determination of total protein concentration in tear and 
conjunctival impression cytology samples: All total protein 
determinations were conducted using the DC Protein Assay 
Kit, following the manufacturer’s instructions. Five µl of each 
CIC protein extract and 1 µl of each tear sample were diluted 
to a total of 10 µl in distilled water and assayed in duplicate.
Electrophoresis and immunoblotting: Samples were thawed 
at room temperature and diluted to the appropriate final 
concentrations in sample buffer (247 mM Tris-HCl, pH 8.6, 
2% SDS (w/v), 50 mM dithiothreitol, 1X Complete Protease 
Inhibitor, 10% glycerol, 0.002% (w/v) Bromophenol blue). 
Protein samples were subjected to agarose gel electrophoresis 
using a SE600 vertical gel unit (Hoefer Scientfic, San Fran-
cisco, CA). A titration of MUC16 standard antigen (CA125) 
or MUC1 standard antigen (CA15–3) was run on each gel to 
Table 1. Sequence of PrimerS and ProbeS uSed for Gene amPlificaTion in real Time rT–Pcr
Gene Forward primer Reverse primer Taqman probe
MUC1 CTGGTCTGTGTTCTGGTTGC CCACTGCTGGGTTTGTGTAA 6FAM-GAAAGAACTACGGGCAGCTG




Table 2. Summary of clinical daTa aSSociaTed wiTh comPleTe cohorT of Pmw enrolled in STudy (n=39)
Measure Value Range
Mean Age 61.4±8.5 52–79
Mean Total OSDI Score 17.7±15.3 0–60
Mean Ocular Symptoms OSDI SubScore 16.8±16.4 0–65
Mean Vision Related Function OSDI SubScore 16.1±15.1 0–56
Mean Environmental OSDI SubScore 21.4±25.8 0–92
Mean NITBUT 5.31±2.8 s 2.9–18.5 s
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normalize data and facilitate semiquantitation of the samples, 
through linear regression analysis. For MUC1, 6 µg of total 
tear protein or 20 µg of CIC total protein extract was loaded 
per lane (determined from preliminary experiments, data not 
shown). For MUC16, 4.0 µg of tear total protein or 5.0 µg 
of total CIC protein was loaded per lane. Following separa-
tion, the protein was vacuum transferred to nitrocellulose 
membranes. Membranes were fixed by heating at 70 °C for 
30 min, air dried for 12 h, and then blocked 0.1% w/v bovine 
serum albumin (BSA) in phosphate buffered saline (PBS; 137 
mM sodium chloride, 2.7 mM potassium chloride, 10 mM 
sodium phosphate, pH 7.4) + 0.05% v/v Tween-20 (=PBS-T) 
for 1 h at room temperature. Blots were incubated overnight 
in appropriate antibody (DF3, 1: 40 or OC 125, 1:250) diluted 
in PBS-T and 0.1% BSA at 4 °C. After rinsing, blots were 
incubated with secondary antibody (1:5000) in PBS-T + 0.1% 
BSA for 1 h at room temperature. Blots were developed with 
ECL Plus and chemiluminescent signals were imaged with a 
Storm 840 Workstation (Molecular Dynamics; GE Healthcare 
Life Sciences, Baie d’Urfe, Canada). The amount of MUC1 
or MUC16 in each sample and standard were quantified 
with image analysis software (ImageQuant 5.1, Molecular 
Dynamics). Known amounts of CA15–3 or CA125 were 
used to generate standard curves, and using the line-of-best-
fit from the standard curve, the relative amount of MUC1 
or MUC16 was interpolated from the graph. All samples 
produced multiple chemiluminescent signals of varying 
molecular weights. For quantitation, only signals equal to 
and above 150 kDa were used. All data are described in units 
of MUC 1 or MUC 16 standard per microgram total protein.
Ribonucleic acid isolation and reverse transcription: Tubes 
containing 1 ml of RLT buffer and two impression cytology 
samples were allowed to thaw at room temperature and then 
vortexed for 30 s. Membranes were removed, and samples 
were passed through a 21 gauge needle ten times. Extrac-
tion of total RNA proceeded according to the manufacturer’s 
instructions using the DNase step as recommended. The 
final isolation step was conducted with 40 µL of RNase free 
water. cDNA was synthesized from 8 µl of the RNA sample 
using random hexamer primers with the SuperScript III 
First-Strand Synthesis System for RT–PCR according to the 
manufacturer’s instructions.
Real-time quantitative polymerase chain reaction: Multiplex 
PCR reactions containing target (MUC1 or MUC16) and 
endogenous control (glyceraldehyde 3-phosphate dehydro-
genase) oligonucleotide primers were performed in the pres-
ence of gene-specific dye-labeled TaqMan probes (Table 1). 
Briefly, 2 μl of cDNA was used for amplification in a 50 µl 
PCR reaction containing the target and endogenous control 
oligonucleotide primers, control and target TaqMan probes, 
and TaqMan Universal PCR Master Mix. Duplicate samples 
were used for analysis in a 7500 Real-Time PCR System 
Table 3. Summary of clinical daTa aSSociaTed wiTh Sub GrouP analySiS
Measure Asymptomatic (n=12) Symptomatic (n=12) p
Mean Age 62.4±9.9 58.4±4.6 0.22
Mean Total OSDI Score 2.3±2.2 35.2±12.1 <0.0001*
Mean Ocular Symptoms OSDI SubScore 4.2±4.7 34.2±16.8 <0.0001*
Mean Vision Related Function OSDI 
SubScore
1.0±2.4 30.7±12.3 <0.0001*
Mean Environmental OSDI SubScore 0.7±2.4 43.1±27.7 <0.0001*
Mean NITBUT 6.7±4.4 s 4.7±1.6 s 0.15
* denotes statistical significance (p<0.05)
Table 4. Summary of correlaTionS beTween niTbuT and mucin exPreSSion
MUC of Interest Pearson Correlation Coefficient 
(NITBUT versus MUC of Interest)
p value n
Tear Film MUC1 −0.29 0.08 37
Tear Film MUC16 0.05 0.79 26
Membrane Bound MUC1 −0.16 0.35 36
Membrane Bound MUC16 −0.12 0.48 36
MUC1 mRNA −0.12 0.50 33
MUC16 mRNA −0.31 0.08 33
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(Applied Biosystems). Conditions used for amplification 
were as follows: 50 °C for 2 min and then an initial 10 min 
denaturing step at 95 °C. This was followed by 40 cycles 
of denaturing at 95 °C for 30 s, annealing at 60 °C for 30 
s, and extension at 72 °C for 45 s. Normalized reporter dye 
fluorescence (Rn) data were collected during the extension 
step at each cycle. The collected data were analyzed, and fold-
expression changes were calculated using the comparative 
method (2-ΔΔCT) of relative quantification with SDS software 
(v1.3.1; Applied Biosystems). Final data are expressed in rela-
tive quantification (RQ) units.
Statistical analysis: Statistical analysis was performed using 
Statistica Ver7.1 (StatSoft Inc., Tulsa, OK) and Microsoft 
Excel XLfit software (Microsoft, Mississauga, Canada). 
Graphs were plotted using Excel. All data are reported as 
mean±standard deviation. The relationship between mucin 
expression and either OSDI or NITBUT data was calculated 
via Pearson linear correlation (StatPlus:mac LE2009). Statis-
tical differences between asymptomatic and symptomatic 
groups were identified with the Student t test comparison of 
means. Significance was identified at p<0.05 (α=0.05).
RESULTS
In this study, the presence and severity of dry eye were 
assessed by determining symptoms and tear stability (Table 
2). Following our clinical study design, clinical data were 
used only for correlation purposes and did not define inclu-
sion. Post hoc analysis addressed whether relative extremes 
in symptoms defined as asymptomatic (OSDI score=0–6) and 
symptomatic (OSDI score ≥20) were associated with differ-
ential expression of mucin. A summary of all clinical data is 
presented in Table 2 and Table 3. No correlation was found 
between NITBUT and OSDI, nor was a significant difference 
found between OSDI and NITBUT when compared based 
on the presence or absence of moderate symptoms (Table 3).
Mucin quantitation: In some cases, there was insufficient 
sample material to perform all the mucin assays; thus, the 










TOTAL OSDI SCORE OCULAR SYMPTOM 
SUBSCORE




Tear Film MUC 1 −0.11 [0.51] −0.06 [0.70] −0.10 [0.57] −0.12 [0.47]
Tear Film MUC16 −0.33 [0.10] −0.18 [0.39] −0.47 [0.01]* −0.25 [0.22]
Membrane Bound MUC1 0.02 [0.89] −0.03 [0.86] 0.03 [0.88] 0.07 [0.68]
Membrane Bound MUC16 0.05 [0.77] 0.18 [0.29] −0.02 [0.92] −0.06 [0.72]
MUC1 mRNA 0.07 [ 0.69] 0.12 [0.50] −0.03 [0.88] 0.05 [0.76]
MUC16 mRNA 0.33 [0.06] 0.39 [0.02]* 0.12 [0.51] 0.27 [0.13]
* denotes statistical significance (p<0.05).
Table 6. Summary of mucin ProTein and mrna exPreSSion daTa
MUCIN PROTEIN EXPRESSION DATA: Data Expressed in units per microgram total protein
Tear Film MUC1 Capillary tears
Asymptomatic Symptomatic p value
0.04±0.09 (n=11) 0.03±0.03 (n=12) 0.6
Tear Film MUC16 Capillary tears 2.73±1.30 (n=10) 2.20±1.88 (n=8) 0.51
Membrane Bound 
MUC1 CIC 0.012±0.013 (n=12) 0.014±0.012 (n=10) 0.75
Membrane Bound 
MUC16 CIC 14.91±9.48 (n=10) 16.63±8.45 (n=10) 0.70
MUCIN RNA EXPRESSION DATA: Data Expressed in Mean RQ Units
MUC1 mRNA CIC 0.82±0.40 (n=11) 0.93±0.30 (n=9) 0.49
MUC16 mRNA CIC 0.57±0.44 (n=11) 1.52±1.19 (n=9) 0.03*
* denotes statistical significance (p<0.05)
Molecular Vision 2013; 19:970-979 <http://www.molvis.org/molvis/v19/970> © 2013 Molecular Vision 
975
number of data points per analysis varies, as noted in Table 4, 
Table 5, and Table 6. Figure 1 and Figure 2 display representa-
tive quantitative data describing mucin protein concentration.
Correlation between mucin expression, the Ocular Surface 
Disease Index, and non-invasive tear breakup time: Table 
4 and Table 5 summarize results from all correlation 
analyses, which revealed weak and insignificant correla-
tions for all comparisons (NITBUT, total OSDI score, and 
individual OSDI subscores), with the exception of MUC16 
mRNA expression and soluble MUC16 protein concentration 
with OSDI vision related and ocular symptom subscores, 
respectively.
Mucin 1, cell surface associated and mucin 16, cell surface 
associated proteins and messenger ribonucleic acid in tears 
and conjunctival epithelial cells derived from asymptomatic 
and symptomatic participants: A post hoc subgroup analysis: 
As presented in Table 6, direct comparison of a subset of 
data from this study indicated that soluble and membrane-
bound MUC1 and MUC16 concentration remained invariant 
between the symptomatic and asymptomatic study groups. 
The same comparison also revealed that MUC1 mRNA 
Figure 1. Western blot. Panel A s an example of MUC1 western blot from impression cytology samples (membrane bound mucin 1 [MUC1]). 
Lanes 1–19 are participant samples. Lanes 20–23 are MUC1 standards (CA15–3; 0.1, 0.2, 0.4, and 0.6 units). MW are molecular weight 
markers from 41 to 460 kDa (kD) beside the accompanying band. Panel B is an example of MUC1 western blot from tear samples (soluble 
MUC1). Lanes 1–17 are participant samples. Lanes 18–21 are MUC1 standard (CA15–3; 0.1, 0.4, 0.8, and 1 unit). C: The sample regression 
curve (from A) was created by graphing applied concentration of MUC1 standard (CA15–3) against the optical density of the resulting 
band immunoreactivity. Total MUC1 concentration was quantified by interpolation from this curve. For analysis purposes, all sample 
chemiluminescent signals at and above 150 kDa were used.
Molecular Vision 2013; 19:970-979 <http://www.molvis.org/molvis/v19/970> © 2013 Molecular Vision 
976
expression remained unchanged, whereas significant down-
regulation (p=0.03) of MUC16 mRNA was found in the 
symptomatic group.
DISCUSSION
In this study, we explored the relationship between the quan-
tity of MUC1 and MUC16 protein and mRNA with dry eye 
symptoms and tear stability in a cohort of PMW that were 
recruited without bias of specific inclusion criteria. We chose 
Figure 2. Western blot. Panel A is an example of MUC16 western blot from impression cytology samples (membrane bound MUC16). 
Lanes 1–21 are participant samples. Lanes 22–26 are MUC16 standards (CA125; 5, 10, 32, 60, and 74 units). MW are molecular weight 
markers from 41 to 460 kDa (kD) beside the accompanying band. Panel B is an example of MUC16 western blot from tear samples (soluble 
MUC16). Lanes 1–7 are participant samples. Lanes 8–12 are MUC16 standard (CA125; 5, 10, 20, 40, and 60 units). C: The sample regression 
curve (from B) was created by graphing the applied concentration of MUC16 standard (CA125) against the optical density of the resulting 
band immunoreactivity. Total MUC16 concentration was quantified by interpolation from this curve. For analysis purposes, all sample 
chemiluminescent signals at and above 150 kDa were used.
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this objective and clinical design because significant confu-
sion exists in the literature about the potential role altered 
mucin expression may play in dry eye. Specifically, data exist 
supporting increased, decreased, and no change in mucin 
concentration associated with dry eye. Complicating inter-
pretation of these results is a multitude of study variables, 
including different dry eye subgroups, inclusion and exclu-
sion criteria, study population size, and analytical methods. 
Thus, beyond our group’s research interests in PMW, step-
ping back and examining the broader picture of whether any 
significant findings could be uncovered was of value. Based 
on our analysis, including a post hoc exploration of absolute 
mucin concentration in asymptomatic control and moderate 
symptomatic dry eye subjects, we conclude that, at least in 
PMW, mucin expression has no obvious role in either dry eye 
symptomology or the maintenance of tear stability.
Data from this study generally failed to uncover any 
correlation between MUC1 or MUC16 protein concentration 
or MUC1 mRNA expression compared to a range of symptom 
data (total OSDI scores ranging from 0 to 60 and all asso-
ciated sub scores) or tear stability data (range, 18.5–2.9 s). 
The two significant, albeit marginally, correlated findings 
were MUC16 mRNA expression and soluble MUC16 protein 
concentration with OSDI ocular symptom and vision related 
subscores, respectively.
Following the lack of compelling findings in our correla-
tion survey, a subgroup analysis was performed post hoc to 
separate out those subjects who were essentially void of dry 
eye symptoms (OSDI ≤6) compared to those with moderate to 
severe symptoms (OSDI ≥20) to examine the hypothesis that 
a biologic signal could be discerned only with more moderate 
disease. This exploration also failed to uncover significant 
findings, with the exception of downregulation in MUC16 
mRNA expression in the symptomatic group.
Our data are in partial agreement with a recently 
published study [25], which concluded that symptomatic 
PMW appear to launch a compensatory response to ocular 
irritation through significant upregulation in mucin expres-
sion. In general, our data failed to demonstrate significant 
correlations, and where significance was found, we concluded 
that the increasing symptoms were associated with increased 
expression of MUC16 mRNA but lower tear film MUC16. 
Both studies used symptoms as a focal point, with Gipson 
et al. [25] using symptoms as the primary means of defining 
dry eye and our study performing a subgroup analysis to 
explore this association specifically. Different question-
naires were used; thus, gauging the severity of symptoms in 
the two studies is difficult, leaving open the possibility that 
mucin expression is sensitive to small changes in symptoms, 
although this is unlikely. In Gipson et al.’s study, additional 
inclusion criteria were used, including documented history 
of dry eye ≥3 months and current use of artificial tears. 
Thus, a potentially more advanced form of dry eye may have 
been sampled in Gipson et al.’s study, as in our subgroup 
analysis, no significant difference in tear stability was found 
between the two groups. Perhaps of greatest note is study 
size. Although our study initially enrolled 39 subjects, which 
is larger than a typical “biomarker” study, it is clear from the 
data standard deviations that much larger sample sizes (such 
as that employed by Gipson et al.) may be needed to gain 
insight into true data significance.
Our findings are largely in contrast with the majority 
of published data, which generally support the hypothesis 
that altered (up- or downregulation) mucin expression is 
associated with dry eye. However, several consistent find-
ings were found, including reports by Argüeso et al. [22] and 
Caffery et al. [20,21], who reported no or few differences 
in the expression of MUC1, MUC4, or MUC16 mRNA or 
protein expression between keratoconjunctivitis sicca (KCS) 
and control groups.
In conclusion, our study of 39 PMW failed to uncover a 
significant association between mucin expression and either 
dry eye symptoms or tear stability. Furthermore, in a post hoc 
exploratory review of a small subset of our data polarizing 
groups between asymptomatic and moderate symptomatic, 
the only difference in mucin expression differentiating the 
groups was a reduction in MUC16 mRNA. Given the overall 
lack of consistency within the mucin expression literature 
as a whole in addition to the lack of evidence supporting a 
clinical correlation between mucin expression and presence or 
absence of dry eye, concluding what, if any role(s) alteration 
in mucin expression plays in the pathophysiology of dry eye 
or the validity of targeting mucin expression as a therapeutic 
treatment strategy for dry eye is difficult.
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